Oregon 2023 Regular Session

Oregon House Bill HB2833

Introduced
1/9/23  
Refer
1/16/23  

Caption

Relating to naloxone; prescribing an effective date.

Impact

The proposed legislation has the potential to significantly alter state laws regarding the distribution of naloxone. It is expected to facilitate easier access for individuals and community organizations, ultimately contributing to a reduction in overdose deaths. The bill seeks to modify existing regulations surrounding opioid prescriptions and naloxone distribution, which may enhance public health efforts throughout the state. However, the effectiveness of these changes will depend on the implementation and the engagement of healthcare providers in the community.

Summary

House Bill 2833 addresses the prescribing and distribution of naloxone, a critical medication used to reverse opioid overdoses. The bill aims to improve access to naloxone in order to alleviate the impacts of the ongoing opioid crisis in the state. Supporters of the bill argue that by streamlining the prescribing process, more individuals at risk of opioid overdose will have access to this life-saving medication. The focus is on enhancing public health responses to the epidemic, particularly for vulnerable populations who may not have consistent healthcare access.

Sentiment

The sentiment surrounding HB 2833 appears largely positive, particularly among public health advocates, healthcare providers, and families affected by the opioid crisis. Many view this bill as a proactive step towards combatting a pressing public health issue. However, some concerns have been raised regarding the adequacy of educational efforts for those prescribed naloxone and the necessity of additional support systems for overdose survivors. Nonetheless, the overall narrative supports legislative action to provide better resources and tools in addressing opioid overdoses.

Contention

Despite broad support, notable points of contention include the challenges related to training and education about naloxone for both patients and healthcare providers. Opponents of the bill may argue that merely increasing access to naloxone does not address the root causes of addiction and may inadvertently encourage riskier drug use. Additionally, ensuring that naloxone is effectively utilized and understood in various communities, especially among marginalized groups, remains a pressing concern. There is an ongoing debate about the balance between access to medications like naloxone and the necessity of comprehensive addiction treatment services.

Companion Bills

No companion bills found.

Previously Filed As

OR SB0401

Health: pharmaceuticals; co-prescribing of naloxone with opioid drugs; require. Amends sec. 17744b of 1978 PA 368 (MCL 333.17744b).

OR SB0087

Naloxone Amendments

OR HB4110

Relating to ibogaine; prescribing an effective date.

OR HB3094

Relating to drug treatment; prescribing an effective date.

OR HB3046

Relating to pharmacy; prescribing an effective date.

OR SB1003

Relating to death with dignity; prescribing an effective date.

OR SB3588

School Access to Naloxone Act of 2026

OR HB2381

Relating to pregnancy resources; prescribing an effective date.

OR HB4070

Relating to health care; and prescribing an effective date.

OR SB1548

Relating to marijuana; prescribing an effective date.

Similar Bills

No similar bills found.